Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies

D. L. Darrington, J. M. Vose, J. R. Anderson, P. J. Bierman, M. R. Bishop, W. C. Chan, M. E. Morris, E. C. Reed, W. G. Sanger, S. R. Tarantolo, D. D. Weisenburger, A. Kessinger, J. O. Armitage

Research output: Contribution to journalArticle

309 Citations (Scopus)

Abstract

Purpose: To analyze the risk of developing myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML) following autologous bone marrow transplantation (ABMT) or peripheral stem-cell transplantation (PSCT) and to determine the impact on failure-free survival (FFS). Patients and Methods: Patients underwent ABMT or PSCT for the treatment of Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL) at the University of Nebraska Medical Center. For those patients who went on to develop MDS/AML, controls were selected and a case-control-within-a-cohort study undertaken. Results: Twelve patients developed MDS or AML a median of 44 months following ABMT/PSCT. The cumulative incidence (P = .42) and the conditional probability (P = .32) of MDS/AML were not statistically different between HD and NHL patients. Age greater than 40 years at the time of transplants (P = .05) and receipt of a total-body irradiation (TBI)-containing regimen (P = .06) were predictive for developing MDS/AML in patients with NHL. Conclusion: There is an increased risk of MDS/AML following ABMT/PSCT for lymphoid malignancies. NHL patients age ≥ 40 years at the time of transplant and who received TBI are at greatest risk.

Original languageEnglish (US)
Pages (from-to)2527-2534
Number of pages8
JournalJournal of Clinical Oncology
Volume12
Issue number12
StatePublished - Jan 1 1994

Fingerprint

Myelodysplastic Syndromes
Stem Cell Transplantation
Chemoradiotherapy
Acute Myeloid Leukemia
Peripheral Blood Stem Cell Transplantation
Autologous Transplantation
Bone Marrow Transplantation
Incidence
Non-Hodgkin's Lymphoma
Neoplasms
Whole-Body Irradiation
Hodgkin Disease
Transplants
Cohort Studies
Survival

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies. / Darrington, D. L.; Vose, J. M.; Anderson, J. R.; Bierman, P. J.; Bishop, M. R.; Chan, W. C.; Morris, M. E.; Reed, E. C.; Sanger, W. G.; Tarantolo, S. R.; Weisenburger, D. D.; Kessinger, A.; Armitage, J. O.

In: Journal of Clinical Oncology, Vol. 12, No. 12, 01.01.1994, p. 2527-2534.

Research output: Contribution to journalArticle

Darrington, D. L. ; Vose, J. M. ; Anderson, J. R. ; Bierman, P. J. ; Bishop, M. R. ; Chan, W. C. ; Morris, M. E. ; Reed, E. C. ; Sanger, W. G. ; Tarantolo, S. R. ; Weisenburger, D. D. ; Kessinger, A. ; Armitage, J. O. / Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies. In: Journal of Clinical Oncology. 1994 ; Vol. 12, No. 12. pp. 2527-2534.
@article{0ec1897a4a654cf9a06d0aa3cf6225e5,
title = "Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies",
abstract = "Purpose: To analyze the risk of developing myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML) following autologous bone marrow transplantation (ABMT) or peripheral stem-cell transplantation (PSCT) and to determine the impact on failure-free survival (FFS). Patients and Methods: Patients underwent ABMT or PSCT for the treatment of Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL) at the University of Nebraska Medical Center. For those patients who went on to develop MDS/AML, controls were selected and a case-control-within-a-cohort study undertaken. Results: Twelve patients developed MDS or AML a median of 44 months following ABMT/PSCT. The cumulative incidence (P = .42) and the conditional probability (P = .32) of MDS/AML were not statistically different between HD and NHL patients. Age greater than 40 years at the time of transplants (P = .05) and receipt of a total-body irradiation (TBI)-containing regimen (P = .06) were predictive for developing MDS/AML in patients with NHL. Conclusion: There is an increased risk of MDS/AML following ABMT/PSCT for lymphoid malignancies. NHL patients age ≥ 40 years at the time of transplant and who received TBI are at greatest risk.",
author = "Darrington, {D. L.} and Vose, {J. M.} and Anderson, {J. R.} and Bierman, {P. J.} and Bishop, {M. R.} and Chan, {W. C.} and Morris, {M. E.} and Reed, {E. C.} and Sanger, {W. G.} and Tarantolo, {S. R.} and Weisenburger, {D. D.} and A. Kessinger and Armitage, {J. O.}",
year = "1994",
month = "1",
day = "1",
language = "English (US)",
volume = "12",
pages = "2527--2534",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "12",

}

TY - JOUR

T1 - Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies

AU - Darrington, D. L.

AU - Vose, J. M.

AU - Anderson, J. R.

AU - Bierman, P. J.

AU - Bishop, M. R.

AU - Chan, W. C.

AU - Morris, M. E.

AU - Reed, E. C.

AU - Sanger, W. G.

AU - Tarantolo, S. R.

AU - Weisenburger, D. D.

AU - Kessinger, A.

AU - Armitage, J. O.

PY - 1994/1/1

Y1 - 1994/1/1

N2 - Purpose: To analyze the risk of developing myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML) following autologous bone marrow transplantation (ABMT) or peripheral stem-cell transplantation (PSCT) and to determine the impact on failure-free survival (FFS). Patients and Methods: Patients underwent ABMT or PSCT for the treatment of Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL) at the University of Nebraska Medical Center. For those patients who went on to develop MDS/AML, controls were selected and a case-control-within-a-cohort study undertaken. Results: Twelve patients developed MDS or AML a median of 44 months following ABMT/PSCT. The cumulative incidence (P = .42) and the conditional probability (P = .32) of MDS/AML were not statistically different between HD and NHL patients. Age greater than 40 years at the time of transplants (P = .05) and receipt of a total-body irradiation (TBI)-containing regimen (P = .06) were predictive for developing MDS/AML in patients with NHL. Conclusion: There is an increased risk of MDS/AML following ABMT/PSCT for lymphoid malignancies. NHL patients age ≥ 40 years at the time of transplant and who received TBI are at greatest risk.

AB - Purpose: To analyze the risk of developing myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML) following autologous bone marrow transplantation (ABMT) or peripheral stem-cell transplantation (PSCT) and to determine the impact on failure-free survival (FFS). Patients and Methods: Patients underwent ABMT or PSCT for the treatment of Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL) at the University of Nebraska Medical Center. For those patients who went on to develop MDS/AML, controls were selected and a case-control-within-a-cohort study undertaken. Results: Twelve patients developed MDS or AML a median of 44 months following ABMT/PSCT. The cumulative incidence (P = .42) and the conditional probability (P = .32) of MDS/AML were not statistically different between HD and NHL patients. Age greater than 40 years at the time of transplants (P = .05) and receipt of a total-body irradiation (TBI)-containing regimen (P = .06) were predictive for developing MDS/AML in patients with NHL. Conclusion: There is an increased risk of MDS/AML following ABMT/PSCT for lymphoid malignancies. NHL patients age ≥ 40 years at the time of transplant and who received TBI are at greatest risk.

UR - http://www.scopus.com/inward/record.url?scp=0028110040&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028110040&partnerID=8YFLogxK

M3 - Article

C2 - 7989926

AN - SCOPUS:0028110040

VL - 12

SP - 2527

EP - 2534

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 12

ER -